hyperprolactinaemia

in review 4 min read Updated 2026-11-19
hyperprolactinaemia

A single unstressful serum prolactin confirms hyperprolactinaemia (repeat if <5× ULN per Pituitary Society 2023). Always exclude pregnancy, medications (antipsychotics, metoclopramide, verapamil), primary hypothyroidism, and CKD/cirrhosis before attributing elevation to a pituitary tumour. Screen for macroprolactin when mild elevation is asymptomatic, and request 1:100 serial dilution when a large pituitary mass has a paradoxically normal or mildly elevated prolactin (hook effect). Cabergoline is first-line medical therapy, while Pituitary Society 2023 now supports discussing upfront transsphenoidal surgery for well-circumscribed Knosp 0–1 prolactinomas at expert centres.


causes and diagnostic pitfalls

step 1 — exclude physiological, drug, and systemic causes

  • Physiological: pregnancy (always check β-hCG in women of reproductive potential), lactation, chest wall stimulation/trauma, stress, exercise, seizures
  • Medications (dopamine D₂ antagonists or serotonin-enhancing drugs): first-generation antipsychotics, risperidone/paliperidone, metoclopramide, domperidone, methyldopa, verapamil, SSRIs, opioids, oestrogens (note: aripiprazole is a partial D₂ agonist and rarely raises PRL)
  • Systemic: primary hypothyroidism (high TRH stimulates lactotrophs — check TSH and treat before pursuing pituitary MRI), CKD (decreased PRL clearance), liver failure
  • Pituitary/parasellar:
    • Prolactinoma: level generally correlates with tumour size (microprolactinoma <10 mm typically 50–200 µg/L; macroprolactinoma ≥10 mm usually >200–250 µg/L)
    • Stalk effect (pituitary stalk compression blocking hypothalamic dopamine): non-functioning pituitary adenoma, craniopharyngioma, hypophysitis — typically raises PRL mildly to moderately (usually <100–200 µg/L)

step 2 — biochemical pitfalls (ES 2011; 2023 consensus)

  • Macroprolactinaemia: biologically inactive IgG-bound PRL multimers — order PEG precipitation for macroprolactin in asymptomatic or clinically discordant hyperprolactinaemia (especially PRL <200 µg/L) to avoid unnecessary MRI and dopamine agonist therapy
  • High-dose hook effect: very high PRL saturates both capture and signal antibodies in two-site immunoassays, yielding a falsely normal or mildly elevated reading — always request 1:100 serial dilution in any patient with a pituitary macroadenoma and paradoxically modest PRL (avoids mistaking a giant prolactinoma for a non-functioning adenoma and sending to unnecessary surgery)
  • Drug-induced hyperprolactinaemia: if safe and after consulting the prescriber (especially for antipsychotics), hold or substitute the offending drug (e.g., switch to aripiprazole or quetiapine) and recheck PRL after ≥3 days; if the drug cannot be stopped and onset does not match drug initiation (or PRL >10× ULN, mass effect, or other pituitary deficits), obtain a pituitary MRI. Do not treat asymptomatic drug-induced hyperprolactinaemia; treat long-term hypogonadism/bone loss with oestrogen or testosterone rather than adding a dopamine agonist when antipsychotics cannot be changed

treatment of prolactinoma (2023 consensus)

who to treat

  • Treat: all macroprolactinomas (≥10 mm), any prolactinoma causing mass effect, symptomatic microprolactinomas (oligo/amenorrhoea, infertility, bothersome galactorrhoea, hypogonadism, low bone density)
  • Observe without dopamine agonist: asymptomatic microprolactinomas (natural history rarely progresses; monitor PRL and clinical status; combined OCP alone is an option for premenopausal women with microprolactinoma-related amenorrhoea not seeking fertility)

medical therapy vs upfront surgery

  • Cabergoline (D₂ agonist): first-line medical therapy over bromocriptine (higher efficacy for PRL normalisation and tumour shrinkage, better tolerability, convenient dosing: start 0.25–0.5 mg PO once or twice weekly, typical maintenance 0.5–2 mg/week)
    • Ontario: cabergoline is covered under ODB LU 656 for hyperprolactinaemia
    • Adverse effects: nausea, postural dizziness, fatigue, nasal congestion, impulse control disorders (hypersexuality, gambling, compulsive shopping — counsel proactively), and CSF rhinorrhoea if a giant invasive macroprolactinoma shrinks rapidly (confirm nasal fluid with β₂-transferrin)
    • Valvulopathy / echocardiography (Pituitary Society 2023): high-dose parkinsonian regimens cause cardiac valve fibrosis; at standard endocrine doses (≤2 mg/week), risk is very low. Consider a baseline echocardiogram if long-term or high-dose therapy (>2 mg/week) is anticipated, repeat every 2–3 years if on >2.0 mg/week, and repeat after 5–6 years if on ≤2.0 mg/week (or anytime a murmur develops)
  • Upfront transsphenoidal surgery (Pituitary Society 2023 shift): for microprolactinomas and well-circumscribed, non-invasive macroprolactinomas (Knosp grade 0–1), discuss surgery by an experienced pituitary surgeon alongside cabergoline as a curative first-line option that avoids lifelong medication; Knosp grade ≥2 (cavernous sinus invasion) should receive cabergoline first-line
  • Resistant or intolerant prolactinoma: escalate cabergoline toward maximal tolerated dose (up to ~3.5 mg/week or higher in specialist hands) before declaring resistance, switch bromocriptine failures to cabergoline, then refer for transsphenoidal surgery (radiotherapy or temozolomide reserved for aggressive/malignant tumours)
  • Withdrawal trial: consider tapering and stopping cabergoline after ≥2 years of treatment if serum PRL is normalised and MRI shows no visible residual tumour (or marked shrinkage in selected cases), with close biochemical follow-up for recurrence

pregnancy (ES 2011; 2023 consensus)

  • Conception & preconception: cabergoline restores ovulation rapidly — advise barrier contraception while initially shrinking a macroprolactinoma; switching from cabergoline to bromocriptine solely for pregnancy planning is no longer routinely required (both have reassuring early-pregnancy safety data, though bromocriptine has the largest historical dataset)
  • Once pregnancy is confirmed: stop dopamine agonist in microprolactinomas and intrasellar macroprolactinomas (risk of clinically significant enlargement is <3% for microadenomas, up to ~20–30% for untreated macroadenomas; selected macroadenomas abutting the chiasm may continue cabergoline/bromocriptine after specialist review)
  • Monitoring during pregnancy:
    • Do NOT measure serum prolactin during pregnancy (physiologically elevated and uninterpretable)
    • Do NOT perform routine pituitary MRI in asymptomatic patients
    • Monitor clinically each trimester (headaches, vision); if severe headache or visual change develops, perform formal visual field testing followed by pituitary MRI without gadolinium — restart a dopamine agonist if symptomatic tumour enlargement occurs
  • Breastfeeding: safe in microprolactinomas and stable macroprolactinomas (defer restarting dopamine agonist while nursing)

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

Suggest a correction hyperprolactinaemia